Aer Therapeutics, Inc.
John Fahy is the Founder of Aer Therapeutics, Inc. since August 2020. Prior to that, they held the position of Professor of Medicine at UCSF since July 1989.
John Fahy completed their Bachelor of Medicine, Bachelor of Surgery (MBBS) degree at University College Dublin from 1979 to 1985. John later pursued a Master of Science (MSc) in Molecular Medicine at Trinity College Dublin from 2002 to 2003.
This person is not in any teams
Aer Therapeutics, Inc.
Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs. We are focused on treating respiratory diseases with significant unmet need, such as COPD, cystic fibrosis and asthma. Our technology was developed and spun out of Dr. John Fahy’s airway biology lab at University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarson’s glycochemistry lab at University College Dublin and Dr. Anne Marie Healy’s pharmaceutics lab at Trinity College Dublin. The efforts of this research consortium led to over $18M in NIH grant funding, resulting in the identification of our lead therapeutic candidate (AER-01), establishment of preliminary safety and efficacy profiles, and the production of clinical trial API.